Sequential chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, J. | - |
dc.contributor.author | Kim, C.Y. | - |
dc.contributor.author | Park, Y.J. | - |
dc.contributor.author | Lee, N.K. | - |
dc.date.accessioned | 2021-09-06T10:00:48Z | - |
dc.date.available | 2021-09-06T10:00:48Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 2287-979X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/105984 | - |
dc.description.abstract | Background: The purpose of this report is to summarize our clinical experience of patients with stage I/II extranodal natural killer (NK)/T-cell lymphoma, nasal type, treated using sequential chemotherapy followed by radiotherapy (SCRT) or concurrent chemoradiotherapy (CCRT). Methods: Forty-three patients with stage I/II extranodal NK/T-cell lymphoma, nasal type, who received SCRT (16 patients) or CCRT (27 patients) were included in the present analysis. Results: The median follow-up time was 39 months (range, 4-171 months) for all patients, 77 months (range, 4-171 months) for the SCRT group, and 31 months (range, 6-132 months) for the CCRT group. There were no statistically significant differences between the SCRT and CCRT groups with regard to the 3-year progression-free survival (PFS) (56% vs. 41%, P=0.823) and 3-year overall survival (OS) (75% vs. 59%, P=0.670). Univariate analysis revealed that patients with tumors confined to the nasal cavity and patients achieved complete remission had better PFS and OS rates, regardless of the treatment sequence. Multivariate analysis revealed that patients with tumors confined to the nasal cavity and patients aged ≤60 years had better OS rates. Conclusion: The effect of SCRT and CCRT are similar in terms of survival outcomes of patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Our results show that tumors confined to the nasal cavity and an age ≤60 years were associated with a better prognosis. © 2013 Korean Society of Hematology. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.subject | antineoplastic agent | - |
dc.subject | asparaginase | - |
dc.subject | bleomycin | - |
dc.subject | cisplatin | - |
dc.subject | cyclophosphamide | - |
dc.subject | dexamethasone | - |
dc.subject | doxorubicin | - |
dc.subject | epirubicin | - |
dc.subject | etoposide | - |
dc.subject | ifosfamide | - |
dc.subject | methotrexate | - |
dc.subject | prednisolone | - |
dc.subject | vincristine | - |
dc.subject | adult | - |
dc.subject | aged | - |
dc.subject | anemia | - |
dc.subject | article | - |
dc.subject | cancer combination chemotherapy | - |
dc.subject | cancer patient | - |
dc.subject | cancer radiotherapy | - |
dc.subject | cancer surgery | - |
dc.subject | chemoradiotherapy | - |
dc.subject | clinical article | - |
dc.subject | controlled study | - |
dc.subject | female | - |
dc.subject | follow up | - |
dc.subject | human | - |
dc.subject | leukopenia | - |
dc.subject | male | - |
dc.subject | middle aged | - |
dc.subject | mucosa inflammation | - |
dc.subject | multimodality cancer therapy | - |
dc.subject | multiple cycle treatment | - |
dc.subject | nephrotoxicity | - |
dc.subject | NK T cell lymphoma | - |
dc.subject | nose cavity | - |
dc.subject | overall survival | - |
dc.subject | pancreatitis | - |
dc.subject | progression free survival | - |
dc.subject | remission | - |
dc.subject | retrospective study | - |
dc.subject | thrombocytopenia | - |
dc.subject | treatment outcome | - |
dc.subject | treatment response | - |
dc.subject | very elderly | - |
dc.subject | young adult | - |
dc.title | Sequential chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, C.Y. | - |
dc.identifier.doi | 10.5045/br.2013.48.4.274 | - |
dc.identifier.scopusid | 2-s2.0-84891084105 | - |
dc.identifier.bibliographicCitation | Blood Research, v.48, no.4, pp.274 - 281 | - |
dc.relation.isPartOf | Blood Research | - |
dc.citation.title | Blood Research | - |
dc.citation.volume | 48 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 274 | - |
dc.citation.endPage | 281 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001827949 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | antineoplastic agent | - |
dc.subject.keywordPlus | asparaginase | - |
dc.subject.keywordPlus | bleomycin | - |
dc.subject.keywordPlus | cisplatin | - |
dc.subject.keywordPlus | cyclophosphamide | - |
dc.subject.keywordPlus | dexamethasone | - |
dc.subject.keywordPlus | doxorubicin | - |
dc.subject.keywordPlus | epirubicin | - |
dc.subject.keywordPlus | etoposide | - |
dc.subject.keywordPlus | ifosfamide | - |
dc.subject.keywordPlus | methotrexate | - |
dc.subject.keywordPlus | prednisolone | - |
dc.subject.keywordPlus | vincristine | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | anemia | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | cancer combination chemotherapy | - |
dc.subject.keywordPlus | cancer patient | - |
dc.subject.keywordPlus | cancer radiotherapy | - |
dc.subject.keywordPlus | cancer surgery | - |
dc.subject.keywordPlus | chemoradiotherapy | - |
dc.subject.keywordPlus | clinical article | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | follow up | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | leukopenia | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | mucosa inflammation | - |
dc.subject.keywordPlus | multimodality cancer therapy | - |
dc.subject.keywordPlus | multiple cycle treatment | - |
dc.subject.keywordPlus | nephrotoxicity | - |
dc.subject.keywordPlus | NK T cell lymphoma | - |
dc.subject.keywordPlus | nose cavity | - |
dc.subject.keywordPlus | overall survival | - |
dc.subject.keywordPlus | pancreatitis | - |
dc.subject.keywordPlus | progression free survival | - |
dc.subject.keywordPlus | remission | - |
dc.subject.keywordPlus | retrospective study | - |
dc.subject.keywordPlus | thrombocytopenia | - |
dc.subject.keywordPlus | treatment outcome | - |
dc.subject.keywordPlus | treatment response | - |
dc.subject.keywordPlus | very elderly | - |
dc.subject.keywordPlus | young adult | - |
dc.subject.keywordAuthor | Chemoradiotherapy | - |
dc.subject.keywordAuthor | Extranodal NK/T-cell lymphoma | - |
dc.subject.keywordAuthor | Nasal type | - |
dc.subject.keywordAuthor | Treatment outcome | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.